| Article Access Statistics|
| Viewed||1157 |
| Printed||51 |
| Emailed||1 |
| PDF Downloaded||110 |
| Comments ||[Add] |
Click on image for details.
| RESEARCH ARTICLE
|Year : 2012 | Volume
| Issue : 3 | Page : 372-376
Improvement of abnormal liver enzymes after rosiglitazone treatment in Chinese type 2 diabetes
Jing-Quan Zheng1, Kun Wang1, Dee Pei1, Yen-Lin Chen2, Yen-Lin Chang3, Chun-Hsien Hsu3, Tsan-Ming Huang1, Mei-Yu Lin1, Pao-Ying Lin1, Jiunn-Diann Lin4
1 Department of Internal Medicine, Cardinal Tien Hospital, School of Medicine, Catholic Fu-Jen University, Taipei, Taiwan, China
2 Department of Pathology, Cardinal Tien Hospital, School of Medicine, Catholic Fu-Jen University, Taipei, Taiwan, China
3 Department of Family Medicine, Cardinal Tien Hospital, School of Medicine, Catholic Fu-Jen University, Taipei, Taiwan, China
4 Department of Internal Medicine, Division of Endocrinology and Metabolism, Shuang Ho Hospital, School of Medicine, Taipei Medical University, Taipei, Taiwan, China
Objectives: Insulin resistance is one of the important underlying abnormalities of type 2 diabetes. The effect of thiazolidinedione on liver functions has been controversial in different studies. In this study, we evaluated the effect of rosiglitazone on liver enzymes in subjects with type 2 diabetes with and without abnormal liver function.
Materials and Methods: Seventy-three patients with type 2 diabetes taking rosiglitazone 4 mg daily were enrolled in this 3-month study. Forty-two of them had normal liver function (NLF), and 31 had abnormal liver function (ABLF). Blood biochemistries were collected monthly during the treatment period.
Results: At baseline, other than age and liver enzymes, there were no differences in body mass index, fasting plasma glucose, hemoglobin A1c (HbA1c), and lipid profiles between the NLF and ABLF groups. At the end of the treatment, HbA1c was lowered in both groups, but only significantly in the ABLF group ( P = 0.027). More importantly, serum concentrations of both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in the ABLF group decreased significantly (AST: 57.8 ± 26.5 to 47.5 ± 20.2 U/L, P = 0.006; ALT 66.6 ± 35.0 to 51.9 ± 23.5 UL, P = 0.004), while in the NLF group, a similar change was not found.
Conclusion: After 3-month rosiglitazone treatment in subjects with type 2 diabetes with mildly elevated liver enzymes, significant improvement in AST and ALT were observed. Our study provides some hints that rosiglitazone might not be contraindicated in subjects with diabetes with abnormal liver function as previously thought, but further well-designed studies are necessary to clarify this issue.
Department of Internal Medicine, Division of Endocrinology and Metabolism, Shuang Ho Hospital, School of Medicine, Taipei Medical University, Taipei, Taiwan
Source of Support: None, Conflict of Interest: None
[FULL TEXT] [PDF]*